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Background and objective: The high-affinity IgE receptor comprises a tetramer of the ligand-
binding alpha chain, a signal-augmenting beta chain, and a signal-transducing gamma chain di-
mer on mast cells. We hypothesized that the three subsets of the FCER1 gene may play a role in
the development of the aspirin-intolerant asthma (AIA) phenotype and analyzed these genetic
polymorphisms in association with clinical parameters in AIA patients.
Subjects and methods: Six polymorphisms of FCER1 (FCERIA-344C>T, FCER1A-95T>C, MS4A2-
109T>C, MS4A2 E237G, FCER1G-237A>G, FCER1G-54G>T) were genotyped in 126 AIA patients
compared to 177 patients with aspirin-tolerant asthma (ATA) and 222 normal health controls
(NC).
Results: A significant difference in the genotype frequencies of FCER1G-237A>G was detected
between AIA and ATA patients (p < 0.05) both in co-dominant and recessive analysis models,
whereas no significant relationships were identified between the frequencies of the other five
single-nucleotide polymorphisms and AIA, ATA, and NC subjects. In addition, AIA patients car-
rying the homozygous AA genotype of FCER1G-237A>G exhibited significantly higher total se-
rum IgE levels than did those with the GG/AG genotype (pZ 0.012). AIA patients expressing
the CT/TT genotype at FCERIA-344C>T showed a higher prevalence of serum IgE specific to
Staphylococcal enterotoxin A than did those with the CC genotype (pZ 0.008).
Conclusion: The FCER1G-237A>G and FCERIA-344C>T polymorphisms may contribute to the
development of AIA in a Korean population.
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The high-affinity IgE receptor polymorphisms with AIA 1133Introduction
Aspirin-intolerant asthma (AIA) is a clinically distinct
syndrome characterized by the onset of asthma attacks
following the ingestion of aspirin and other non-steroidal
anti-inflammatory drugs (NSAIDs). Symptoms of AIA include
aspirin sensitivity, asthma, and rhino sinusitis. AIA is
observed in 5e15% of adult asthmatic patients and is most
commonly observed in middle-aged females whose clinical
symptoms are more severe than those of aspirin-insensitive
asthma patients.1e3
IgE is thought to play a key role in the pathogenesis of
asthma and other allergic diseases because elevated serum
IgE levels have been closely associated with atopy and
allergic asthma.4 AIA patients, however, have been shown
to exhibit increased levels of serum total and specific IgE
to Staphylococcal superantigens independent of atopic sta-
tus. AIA patients having high serum specific IgE antibody
also showed increased airway hyper responsiveness to
methacholine.5 The other study showed that IgE antibodies
specific for Staphylococcal enterotoxin A (SEA) and Staphy-
lococcal enterotoxin B (SEB) were present in approximately
one half of polyp tissues from patients with nasal polyposis
and the presence of enterotoxin-specific IgE correlated
with the presence of polyclonal IgE antibodies specific for
inhaled allergens. Furthermore, SEA and SEB positive sam-
ples were found to have eosinophils, IL-5, eotaxin and
cys-leukotrienes and they were more likely to be associated
with asthma or aspirin sensitivity.6 We have also reported
that the levels of SEA and SEB specific IgE antibodies in
nasal polyps were higher in AIA than those with ATA and
the levels of enterotoxin-specific IgE correlated with the de-
gree of eosinophilic inflammation.7 During the IgE-mediated
response, IgE binds with a high-affinity IgE receptor, which
consists of a tetramer of a ligand-binding a chain, a signal-
augmenting b, and a signal-transducing g chain dimer. The
receptor is abundantly expressed on the surface ofmast cells
and basophils and is thought to be involved in allergic inflam-
mation of the asthmatic airway.8
The FCER1G gene is located on chromosome 1q23 in
humans. Fc3R1g plays an essential role in the induction of
mast cell degranulation and survival.9e11 To date, the
only study suggesting an association of Fc3R1g with asthma
and allergic diseases reported a statistically insignificant
association of an FCER1G gene polymorphism with systemic
lupus erythematosus.12 The FCER1A gene is located on
chromosome 1q23 and known as the first IgE-binding site
to induce mast cell activation. This initiates receptor stabi-
lization, which is critical to the IgE-mediated allergic
response.13 Although some studies have suggested a possible
role of this genetic polymorphism in allergic asthma and
atopic dermatitis,14,15 no published data support any asso-
ciation with AIA patients.
The MS4A2 gene, the b chain of the high-affinity recep-
tor for immunoglobulin (IgE), is located on chromosome
11q13. The b chain of Fc3R1 is an amplifier for cell surface
expression in association with the alpha chain, as well as an
enhancer for signal-transduction via an immunoreceptor
tyrosine activation motif (ITAM) of the Fc3RI gamma
chain.16 The MS4A2 gene polymorphism is associated
with atopy, asthma, and serum total IgE in asthmaticpatients.17,18 One study reported an association of MS4A2
gene polymorphism with the prevalence of serum IgE spe-
cific to Staphylococcal superantigens in AIA patients.19
We examined whether genetic polymorphisms of FCER1
in mast cells play an important role in AIA pathogenesis
by analyzing the genotypes and haplotypes of three subsets
of FCER1 genes in association with various clinical parame-
ters. We also investigated the possible genetic/environ-
mental component of AIA development by examining the
prevalence of serum IgE specific for three Staphylococcal
superantigens: SEA, SEB, and toxic shock syndrome toxin
1 (TSST-1).Materials and methods
Study subjects
The three study groups of 126 patients with AIA, 177
patients exhibiting aspirin-tolerant asthma (ATA), and 222
normal health controls (NC) were recruited from Ajou
University Hospital, Suwon, Korea. The diagnosis of AIA
was based on a positive response to a lysine-acetyl salicylic
acid (ASA) bronchoprovocative test, which was performed
on all study subjects according to a previously described
method.20 Change of forced expiratory volume (FEV1) in 1 s
was followed up for 5 h following the final dose of the aspi-
rin challenge. The ASA-induced change (%) in FEV1 was
calculated as the percentage of post-challenge FEV1 rela-
tive to pre-challenge FEV1.
Methacholine bronchial challenge tests were performed
as described previously.21 NC individuals were chosen from
the general population using a screening questionnaire in
which they indicated no history of respiratory symptoms
or aspirin hypersensitivity. All NC subjects also exhibited
an FEV1 greater than 80% of predicted, provocation concen-
tration (PC20) methacholine greater than 25 mg/ml, and
normal findings on simple chest radiograms. Atopy was
defined as one or more positive reactions in a skin prick
test using 12 common aeroallergens (Bencard, Brendford,
UK), with histamine and saline controls. To measure spe-
cific IgE, venous blood was collected from the antecubital
vein, allowed to clot for 1e3 h at 4 C and centrifuged at
1500  g for 10 min at 4 C. The serum was aspirated, sep-
arated and stored in aliquots at 20 C until analysis. Se-
rum total IgE, SEA, SEB, and TSST-1 were measured using
the UniCAP system (Pharmacia Diagnostics, Valinge, Swe-
den), according to the manufacturer’s instructions. The
threshold cut off value for specific IgE level is 0.35 KU/L
as measured by UniCAP.
The presence of rhinosinusitis and nasal polyps was
evaluated using a paranasal sinus X-ray and rhinoscopy.
Informed consent was obtained from all subjects, and the
institutional review board of Ajou University Hospital
(Suwon, Korea) approved the study.
SNP identification and genotyping
The single-nucleotide polymorphisms (SNPs) FCERIA-
344C>T, FCERIA-95T>C, MS4A2-109T>C, and MS4A2
E237G were described previously for a Korean
Table 1 Amplifying and extension primers of the candidate genes for SNP genotyping
Gene SNP Position Primers
FCER1A -344C>T Promoter Forward tggcatatgtttggtattcagt
Reverse aatctgtcaatctgtgtacaactatttag
Extension cttagaaaagtgggatgcaagggag
-95T>C Promoter Forward agaaagaagcaaaaccaggc
Reverse aatataggcttaaaccaaaaagca
Extension caaaaagcagxaggaaatgttttctgt
MS4A2 -109T>C Promoter Forward aaaattatgctccaggagtctca
Reverse ataagtttcttggctgattaagatca
Extension tttacttgtgatgaatagaaaaatt
E237G Exon Forward agaggatcgtgtttatgaagaattaaac
Reverse gaatcagagtgttctggacacgt
Extension cttacagtgagttggaagacxcagggg
FCER1G -237A>G Promoter Forward gtggagtggaaaatggca
Reverse actgctggaatcatcttgg
Extension tgtagacagcctttcctgagcgtga
-54G>T Promoter Forward aaagcatgggggaaggcg
Reverse actgctggaatcatcttgg
Extension agggggactctgtggtcagggaact
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healthy Korean volunteers. Promoter regions were se-
quenced to examine SNPs by using the ABI Prism 3100 DNA
analyzer (Applied Biosystems, Foster City, CA, USA).
Sequencing analysis was based on GenBank sequences.
Sequence variants were verified using chromatograms.
SNPs in the promoter region of FCERIG were screened by
SNP-IT assays. Information regarding SNPs in the promoter
region of Fc3RIG was obtained from the NCBI SNP database
and two SNPs were selected.
SNP genotyping was performed using SNP-IT assays
with the SNPstream 25K system (Orchid Biosciences,
Princeton, NJ, USA). The region of genomic DNA spanning
the polymorphic site was amplified using PCR with one
phosphothiolated primer and one regular PCR primer. TheTable 2 Clinical characteristics of the study subjects
AIA (NZ 126) ATA (NZ 177)
Age (year)a 44.65  12.95 39.95  13.89
Sex (male/total) 48/126 (38.1%) 98/177 (44.6%)
Atopy (presence/total) 66/119 (55.7%) 118/172 (68.6%)
FEV1 (%)
a 78.09  25.75 87.73  22.48
Fall_FEV1
a 23.48  10.07 7.15  3.83
Log [PC20 methacholine
(mg/mL)]a
0.06  0.66 0.48  0.72
Serum total
IgE (IU/mL)a
358.70  436.59 423.96  698.08
Log [serum total
IgE (IU/mL)]a
2.24  0.57 2.24  0.66
Rhinosinusitis
(presence/total)
83/101 (82.2%) 130/171 (76.0%)
a This value was presented as means  SD. Values in bold indicate
tolerant asthma; NC, normal control; FEV1%, forced expiratory volume
applicable.sequences of the amplifying and extension primers for
FCERIA-344C>T (rs 2427827), FCERIA-95T>C (rs 2251746),
MS4A2-109T>C (rs 1441586) MS4A2 E237G (rs 569108),
FCERIG-237A>G (rs 11587213), and FCERIG-54G>T (rs
2070901) were shown (Table 1). BIONEER (http://www.bioneer.
com) programme was used for primer composition and
further verified by NCBI BLAST (http://www.ncbi.nlm.nih.
gov/blast/Blast.cgi).
Statistical analysis
Significant departures of genotype frequency from Hardye
Weinberg equilibrium at each polymorphic site were tested
using chi-square analyses. Haplotypes of the Fc3RI gene
were analyzed using Haploview v2.0 based on theNC (NZ 222) p-value
AIA vs. ATA AIA vs. NC ATA vs. NC
35.83  15.05 0.003 <0.001 <0.001
102/222 (45.9%) 0.288 0.177 0.840
28/189 (14.8%) 0.026 <0.001 <0.001
NA 0.001 NA NA
NA 0.001 NA NA
NA <0.001 NA NA
NA 0.379 NA NA
1.71  0.58 0.987 <0.001 <0.001
NA 0.287 NA NA
significant p value. AIA, aspirin-intolerant asthma; ATA, aspirin-
in 1 s; IgE, immunoglobulin E. NZ number of patients, NAZ not
Table 3 Genotype and allele frequencies of FCER1
Loci Genotype AIA ATA NC p-value
AIA vs. ATA AIA vs. NC ATA vs. NC
FCERIA-344C>T CC 86/125 113/177 148/222 0.296 0.904 0.390
(68.80%) (63.80%) (66.70%)
CT 34/125 57/177 70/222 0.906 0.204 0.197
(27.20%) (32.20%) (31.50%)
TT 5/125 7/177 4/222 0.231 0.557 0.607
(4.00%) (4.00%) (1.80%)
*q 0.176 0.201 0.176 0.287 0.905 0.401
Total 125 177 222
FCERIA-95T>C TT 120/126 164/177 200/222 0.468 0.109 0.319
(95.20%) (92.70%) (90.10%)
CT 6/126 13/177 22/222 NA NA NA
(4.80%) (7.30%) (9.90%)
CC 0.468 0.109 0.319
*q 0.024 0.037 0.050 0.475 0.117 0.330
Total 126 177 222
MS4A2-109T>C TT 63/126 91/177 99/222 0.901 0.517 0.243
(50.00%) (51.40%) (44.60%)
CT 56/126 74/177 104/222 0.717 0.369 0.631
(44.40%) (41.80%) (46.80%)
CC 7/126 12/177 19/222 0.742 0.739 0.226
(5.60%) (6.80%) (8.60%)
*q 0.278 0.277 0.320 0.905 0.534 0.258
Total 126 177 222
MS4A2 E237G AA 96/126 134/177 151/222 0.926 0.252 0.093
(76.20%) (75.70%) (68.00%)
AG 27/126 40/177 65/222 0.542 0.962 0.569
(21.40%) (22.60%) (29.30%)
GG 3/126 3/177 6/222 0.926 0.187 0.088
(2.40%) (1.70%) (2.70%)
*q 0.131 0.130 0.173 0.925 0.252 0.094
Total 126 177 222
FCER1G-237A>G AA 111/126 136/177 183/222 0.035 0.114 0.213
(88.10%) (76.80%) (82.40%)
AG 15/126 40/177 35/222 1.000 0.999 0.316
(11.90%) (22.60%) (15.80%)
GG 0/126 1/177 4/222 0.039 0.184 0.097
(0.00%) (0.60%) (1.80%)
*q 0.060 0.119 0.097 0.043 0.102 0.210
Total 126 177 222
FCER1G-54G>T GG 35/126 39/168 62/221 0.689 0.721 0.701
(27.80%) (23.20%) (28.10%)
GT 54/126 85/168 101/221 0.740 0.548 0.777
(42.90%) (50.60%) (45.70%)
TT 37/126 44/168 58/221 0.315 0.998 0.361
(29.40%) (26.20%) (26.20%)
*q 0.508 0.515 0.491 0.681 0.706 0.695
Total 126 168 221
Values in bold indicate significant p value. *qZminor allele frequency.
The high-affinity IgE receptor polymorphisms with AIA 1135expectation maximization (EM) algorithm.22 Pairwise
linkage disequilibrium (LD) between SNP loci was measured
using the absolute value of Lewontin’s D0 and r2.23 Differ-
ences in the mean values of phenotypic characteristicsamong AIA patients were compared using analysis of
t-tests. Statistical analyses were performed using SPSS
version 11.5 (SPSS Inc., Chicago, IL, USA) with a significance
level of p < 0.05.
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Clinical characteristics of the study subjects
The mean ages of both AIA and ATA patients were
significantly higher than that of the NC group (p < 0.001;
Table 2). The atopy rate was significantly lower for AIA
patients compared to those with ATA (pZ 0.026). The per-
cent fall in forced expiratory volume (FEV1) after the lysine
aspirin inhalation was significantly lower in the AIA patients
compared to the ATA patients (pZ 0.001). The AIA patients
also exhibited significantly lower baseline PC20 methacho-
line compared to the ATA patients (p < 0.001). Significant
differences in serum total IgE were noted for both the AIA
and ATA patients compared to the NCs; however, there
was no significant difference in serum total IgE between
AIA and ATA patients.
Allele, genotype, and haplotype frequencies of
the FCER1 gene with the AIA phenotype
Genetic associations were examined among the six genetic
polymorphisms of FCERIA-344C>T, FCERIA-95T>C, MS4A2-
109T>C, MS4A2 E237G, FCERIG-237A>G, and FCERIG-
54G>T and the three study groups of AIA, ATA, and NC.
The genotype distribution of six polymorphisms did not de-
part significantly from HardyeWeinberg equilibrium
(p>0.05). The genotypic frequency of FCERIG-237A>G
was significantly different between AIA and ATA patients
(Table 3). Specifically, AIA patients showed a significantly
higher frequency of the homozygous AA genotype of
FCERIG-237A>G compared to ATA patients (p < 0.05) both
in co-dominant and recessive analysis models. However,Table 4 Comparison of the clinical characteristics according to
-237A > G
AA AG or GG
Sex (male/total) 43/111 (38.7%) 5/15 (33.3%)
Atopy (presence/total) 58/105 (55.2%) 8/14 (57.1%)
Asthma duration (year)a 6.24  5.29/89 9.58  9.7/12
FEV1 (%)
a 77.31  25.39/108 83.75  28.52/15
Fall_FEV1
a 23.33  9.52/69 24.4  13.56/11
Log [PC20 methacholine
(mg/mL)]a
0.02  0.65/76 0.41  0.68/11
Log [serum total IgE
(IU/mL)]a
2.29  0.54/98 1.89  0.68/14
Serum total IgE
(IU/mL)a
384.10  454.65/98 180.88  214.99/1
Rhinosinustis
(presence/total)
72/90 (80.0%) 11/11 (100.0%)
Specific IgE to SEA
(positive/total)
7/36 (19.4%) 1/4 (25.0%)
Specific IgE to SEB
(positive/total)
10/36 (27.8%) 1/4 (25.0%)
Specific IgE to TSST-1
(positive/total)
7/36 (19.4%) 1/4 (25.0%)
a This value was presented as means  SD. Values in bold indicate
immunoglobulin E; SEA, Staphylococcal enterotoxin A; SEB, Staphylocthere were no significant differences among the test groups
with respect to the allele and genotype frequencies of the
other FCERI SNPs, including FCERIA-344C>T, FCERIA-
95T>C, MS4A2-109T>C, MS4A2 E237G, and FCERIG-54G>T
(p>0.05) (Table 3). Two polymorphisms in the FCER1A
gene were not in linkage disequilibrium (jD0jZ 0.74 and
r2Z 0.01). Two polymorphisms in the MS4A2 and FCER1G
gene were in linkage disequilibrium (jD0jZ 0.95) and
(jD0jZ 0.97) respectively and three common haplotypes,
ht1[TA], ht[CA], ht3[CG] and ht1[AT], ht[AG], ht3[GG]
were constructed utilizing the EM algorithm. No significant
differences in haplotypes frequencies were observed
among the three groups (p>0.05) (data not shown). In addi-
tion, there were no significant associations between clinical
parameters such as atopy, FEV1, log PC20 methacholine,
and rhinosinusitis and any polymorphism within the AIA
patients.FCERIG-237A>G and total serum IgE levels
Of the six target SNPs of the Fc3RI gene, a significant
association was detected between the FCERIG-237A>G
polymorphism and total serum IgE level in AIA patients.
In addition, AIA patients carrying the homozygous AA
genotype of FCERIG-237A>G exhibited significantly higher
levels of total serum IgE than did those with the AG/GG
genotype (pZ 0.012) (Table 4). This association was
not found in ATA patients (p>0.05, data not shown).
Furthermore, no significant associations were found be-
tween the total serum IgE level and the other five SNPs,
including FCERIG-54G>T, FCERIA-344C>T, FCERIA-
95T>C, MS4A2-109T>C, MS4A2 E237G, and FCERIG-
54G>T (Tables 4e6).the genotype of FCERIG in AIA
p-value -54G > T p-value
GG GT or TT
0.783 13/35 (37.14%) 35/91 (38.46%) 1.000
1.000 21/33 (63.64%) 45/86 (52.33%) 0.307
0.070 7.69  6.68/28 6.23  5.73/73 0.279
0.366 77.84  28.36/35 78.2  24.82/88 0.944
0.747 25.02  10.53/20 22.97  9.95/60 0.433
0.066 0.25  0.74/20 0.02  0.64/67 0.179
0.012 2.21  0.68/32 2.26  0.52/80 0.705
4 0.009 436.05  589.26/32 327.76  358.00/80 0.338
0.206 24/29 (82.76%) 59/72 (81.94%) 1.000
1.000 2/12 (16.67%) 6/28 (21.43%) 1.000
1.000 3/12 (25%) 8/28 (28.57%) 1.000
1.000 3/12 (25%) 5/28 (17.86%) 0.677
significant p value. FEV1%, forced expiratory volume in 1 s; IgE,
occal enterotoxin B; TSST-1, toxic shock syndrome toxin 1.
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of FCERI with serum IgE specific for
Staphylococcal superantigens
Asthma-related phenotypes such as atopy, total serum IgE
level, FEV1, and PC20methacholine, aswell as IgE specific for
SEA, SEB, andTSST-1,were examined for associationswith six
polymorphisms of the Fc3RI gene (Tables 4e6). Significant
associations were noted between two SNPs, i.e., FCERIA-
344C>T and FCERIA-95T>C, and the prevalence of serum
IgE specific to SEA. Specifically, AIA patients carrying the
CT/TT genotype at FCERIA-344C>T had a significantly higher
prevalence of SEA-specific IgE than did those with the CC ge-
notype (pZ 0.008). In addition, AIA patients with the CT/CC
genotype at FCERIA-95T>C had a higher prevalence of SEA-
specific IgE than did those with the TT genotype
(pZ 0.035). The FCERIA-95T>C genetic polymorphism was
also significantly associated with the prevalence of IgE spe-
cific for TSST-1, whereby patients carrying the CT/CC
genotype exhibited a significantly higher prevalence than
thosewith thehomozygousTTgenotype (pZ 0.036; Table 5).
However, no such associations were found in case of ATA pa-
tients (p>0.05; data not shown). AIA patients expressing the
TT genotype of the MS4A2-109T>C genetic polymorphism
showed a significantly higher prevalence of IgE specific for
SEB than did those with CT/CC genotype (pZ 0.012). There
was no association between the MS4A2 E237G polymorphism
and IgE specific for SEA, SEB, or TSST-1 (Table 6).
Discussion
We examined six genetic polymorphisms of FCER1A, MS4A2,
and FCER1G for associations with the AIA phenotype inTable 5 Comparison of the clinical characteristics according to
-344C > T
CC CT or TT
Sex (male/total) 34/86 (39.53%) 14/39 (35.9%)
Atopy (presence/total) 44/81 (54.32%) 22/37 (59.46%)
Asthma duration (year)a 7.1  6.61/72 5.54  4.09/28
FEV1 (%)
a 78.96  24.63/85 76.33  28.73/37
Fall_FEV1
a 22.35  8.99/52 25.76  11.89/27
Log [PC20 methacholine
(mg/mL)]a
0.08  0.74/58 0.04  0.47/29
Log [serum total
IgE (IU/mL)]a
2.19  0.6/77 2.38  0.49/34
Serum total
IgE (IU/mL)a
323.84  381.46/77 443.76  542.61/3
Rhinosinustis
(presence/total)
59/71 (83.1%) 23/29 (79.31%)
Specific IgE to SEA
(positive/total)
2/27 (7.41%) 6/13 (46.15%)
Specific IgE to SEB
(positive/total)
6/27 (22.22%) 5/13 (38.46%)
Specific IgE to TSST-1
(positive/total)
5/27 (18.52%) 3/13 (23.08%)
a This value was presented as means  SD. Values in bold indicate
immunoglobulin E; SEA, Staphylococcal enterotoxin A; SEB, Staphyloca Korean population. The FCER1G-237A>G was significantly
associated with the AIA phenotype, as well as total serum
IgE levels, within AIA patients. Fc3R1g is essential for initi-
ating the signal-transduction pathway necessary to induce
cell degranulation, although its intensity is less than that
of endogenous tetrameric Fc3R1.10 The promotion of mast
cell survival by IgE without antigens is mediated by signals
through the ITAM. Therefore, Fc3R1g-mediated signals dif-
ferentially upregulate the receptor expression, activation,
and survival of mast cells.10 No study has examined the ge-
netic association of this polymorphism with the pathogenic
mechanism of AIA, however, recent data suggest that mRNA
levels of Fc3R1g in peripheral blood mononuclear cells are
upregulated by aspirin treatment.25 Even though serum to-
tal IgE may be more important for asthma rather than AIA,
our present statistical significant association of FCER1G-
237A>G and serum total IgE in AIA group cannot be
precluded. Therefore, functional role of this SNP might be
beneficial for AIA pathogenesis. Given our results, we pro-
pose that the FCER1G-237A>G polymorphism may be
a risk factor for AIA susceptibility.
We previously demonstrated a significant association of
FCER1A with aspirin-intolerant chronic urticaria,24 in which
an FCER1A promoter polymorphism was associated with
increased expression of Fc3R1a on mast cells via the en-
hanced release of histamine. Similarly, the study also indi-
cated that the FCER1A-344C>T is associated with total
serum IgE levels in patients with allergic diseases.26 How-
ever, we did not find any significant association between al-
lelic frequencies of FCER1A-344C>T with the total serum
IgE level within the AIA patients, but a significant associa-
tion was detected between FCER1A-344C>T and the
prevalence of SEA-specific serum IgE. Functional role of
FCER1A-344C>T implicated that the reporter plasmidthe genotype of FCERIA in AIA
p-value -95T > C p-value
TT CT or CC
0.843 46/120 (38.33%) 2/6 (33.33%) 1.000
0.691 65/115 (56.52%) 1/4 (25%) 0.322
0.246 6.7  6.12/97 5  1.41/4 0.581
0.607 79.06  24.48/117 59.29  42.81/6 0.311
0.158 23.09  9.62/78 38.85  20.01/2 0.028
0.773 0.07  0.66/82 0.11  0.78/5 0.890
0.107 2.25  0.57/108 2.07  0.48/4 0.543
4 0.249 365.09  442.07/108 186.20  202.42 0.423
0.775 81/98 (82.65%) 2/3 (66.67%) 0.449
0.008 6/38 (15.79%) 2/2 (100%) 0.035
0.451 10/38 (26.32%) 1/2 (50%) 0.479
1.000 6/38(15.79%) 2/2(100%) 0.036
significant p value. FEV1%, forced expiratory volume in 1 s; IgE,
occal enterotoxin B; TSST-1, toxic shock syndrome toxin 1.
Table 6 Comparison of the clinical characteristics according to the genotype of MS4A2 in AIA
-109T > C p-value E237G p-value
TT CT or CC AA AG or GG
Sex (male/total) 23/63 (36.51%) 25/63 (39.68%) 0.855 38/96 (39.58%) 10/30 (33.33%) 0.668
Atopy (presence/total) 33/59 (55.93%) 33/60 (55%) 1.000 47/91 (51.65%) 19/28 (67.86%) 0.192
Asthma duration (year)a 7.46  6.42/52 5.76  5.48/49 0.156 6.89  5.99/78 5.79  6.14/23 0.444
FEV1 (%)
a 77.3  23.9/61 78.88  27.63/62 0.734 76.48  25.43/94 83.34  26.56/29 0.211
Fall_FEV1
a 22.79  8.97/39 24.13  11.09/41 0.555 23.4  9.85/62 23.77  11.09/18 0.892
Log [PC20 methacholine
(mg/mL)]a
0  0.71/43 0.13  0.62/44 0.365 0.08  0.68/68 0.04  0.64/19 0.836
Log [serum total
IgE (IU/mL)]a
2.34  0.58/56 2.15  0.55/56 0.072 2.25  0.57/86 2.21  0.57/26 0.739
Serum total
IgE (IU/mL)a
438.98  508.52/56 278.42  336.10/56 0.052 364.39  448.37/86 339.89  402.85/26 0.803
Rhinosinustis
(presence/total)
43/50 (86%) 40/51 (78.43%) 0.437 66/79 (83.54%) 17/22 (77.27%) 0.534
Specific IgE to SEA
(positive/total)
6/19 (31.58%) 2/21 (9.52%) 0.120 8/28 (28.57%) 0/12 (0%) 0.079
Specific IgE to SEB
(positive/total)
9/19 (47.37%) 2/21 (9.52%) 0.012 10/28 (35.71%) 1/12 (8.33%) 0.124
Specific IgE to TSST-1
(positive/total)
6/19 (31.58%) 2/21 (9.52%) 0.120 7/28 (25%) 1/12 (8.33%) 0.396
a This value was presented as means  SD. FEV1%, forced expiratory volume in 1 s; IgE, immunoglobulin E; SEA, Staphylococcal entero-
toxin A; SEB, Staphylococcal enterotoxin B; TSST-1, toxic shock syndrome toxin 1.
1138 N.S. Palikhe et al.carrying -344T allele exhibited significantly higher promoter
activity in a rat mast cell line (RBL-2H3) compared to -344C
allele. The association of transcription factor Myc-
associated zinc finger protein bound the -344C promoter
and also showed that heterozygous CT genotype of the -
344C>T exhibited greater anti-IgE-mediated histamine
release compared to CC genotype.24
Although, we identified significant associations between
the FCER1A-95T>C polymorphism and serum IgE specific for
SEA and TSST-1, further studies using a larger sample size
are necessary to confirm these associations.
Previous population studies have reported significant
associations between the MS4A2 polymorphism and total
serum IgE levels in asthmatic patients.27,28 However, our
results suggest that this is not the case for AIA patients.
Kim et al.19 suggested a synergistic effect between the
MS4A2-109T>C polymorphism and serum IgE specific to
SEB in AIA patients. These results were supported by our
current study population. It has been proposed that this
genetic/environmental interaction occurs via the binding
of SEB-specific IgE to its high-affinity receptor Fc3R1 on
the mast cell surface, resulting in mast cell activation and
the enhanced release of inflammatory mediators and cyto-
kines, which could ultimately contribute to AIA develop-
ment. In vitro functional study of MS4A2-109T>C by
luciferase reporter assays showed that Fc3R1b-109T allele
was associated with higher promoter activity in both RBL-
2H3 and A549 cell lines.19 Therefore, increased expression
of Fc3R1b-109T on mast cells may enhance the inflamma-
tory mediators and Th2 cytokines and development of AIA.
With respect to the role of Staphylococcal superantigens
in AIA pathogenesis, it is possible that AIA patients with
high levels of IgE specific for the three Staphylococcal
superantigens exhibit more severe airway hyper-responsiveness.8 Specifically, the Staphylococcal superanti-
gens may stimulate mast cell activation and polyclonal ac-
tivation of T cells and antigen-specific CD4 þ T cells with
the release of Th2 cytokines and other proinflammatory
mediators. This would promote the activation of IgE-pro-
ducing B cells, which could contribute to the development
of airway inflammation in AIA patients.29,30 Given our data,
we suggest that two genetic polymorphisms, FCER1A-
344C>T and MS4A2-109T>C, may interact with the specific
IgE response to Staphylococcus aureus, which enhances the
progression of airway inflammation in AIA patients.
In conclusion, we examined three sets of FCER1A, MS4A2
and FCER1G genetic polymorphism in AIA patients compar-
ing with ATA and NC. Among them, FCERIG-237A>G may be
more susceptible in AIA in a Korean population in associa-
tion with serum total IgE and it is also speculated that
FCER1A-344C>T and MS4A2-109T>C may increase the se-
verity of AIA in association with specific IgE responses to
Staphylococcal superantigens.Conflict of interest statement
There are no conflicts of interest.
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